Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate.

导出 LinkOut

翻译打印收藏纠错

第一作者： Taotao,Zhou

第一单位： Department of Internal Medicine I, University Hospital of Bonn, Bonn, Germany.

作者： Taotao,Zhou ^[1] ; Robert,Mahn ^[1] ; Christian,Möhring ^[1] ; Farsaneh,Sadeghlar ^[1] ; Carsten,Meyer ^[2] ; Marieta,Toma ^[3] ; Barbara,Kreppel ^[4] ; Markus,Essler ^[4] ; Tim,Glowka ^[5] ; Hanno,Matthaei ^[5] ; Jörg C,Kalff ^[5] ; Christian P,Strassburg ^[1] ; Maria A,Gonzalez-Carmona ^[1]

作者单位： Department of Internal Medicine I, University Hospital of Bonn, Bonn, Germany. ^[1] Department of Radiology, University Hospital of Bonn, Bonn, Germany. ^[2] Department of Pathology, University Hospital of Bonn, Bonn, Germany. ^[3] Department of Nuclear Medicine, University Hospital of Bonn, Bonn, Germany. ^[4] Department of Visceral Surgery, University Hospital of Bonn, Bonn, Germany. ^[5]

关键词 BRCA2 PDL1 case report cholangiocarcinoma targeted therapy

DOI 10.3389/fonc.2022.933943

PMID 35957899

发布时间 2022-08-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in oncology

2022年12卷

933943页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除